Morphology of Retinal Hemangioblastoma in von Hippel-Lindau Disease Revealed by Optical Coherence Tomography Angiography
Klinische Monatsblätter für Augenheilkunde · 10.02.2025
DOI: 10.1055/a-2501-8628 ↗Kurz gefasst
Fachartikel in der Zeitschrift Klinische Monatsblätter für Augenheilkunde, erschienen am 10.02.2025. Verfasst von Yannik Laich und 13 weiteren Autor:innen. Beteiligte Einrichtung: Eye Center, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
To characterize different growth patterns of retinal hemangioblastomas (RHs) in patients with von Hippel-Lindau disease (VHLD) using swept-source optical coherence tomography angiography (SS-OCTA).
Methods
Single-center observational cross-sectional study. SS-OCTA B-scans were centered over primary treatment-naïve RHs to display the perfusion in the inner, middle, and outer areas (IA, MA, OA). Distinctive growth patterns were characterized using K-means cluster analysis of the flow signal.
Results
Annual screening of 201 patients with VHLD revealed 49 patients with 85 RHs (41 recurrent, 44 primary treatment-naïve RHs). High-quality SS-OCTA images were available for 24 primary RHs and were pooled with scans of the treatment-naïve form of 6 recurrent RHs, which were taken at a prior visit, for further analysis. Out of 30 primary RHs, 18 were located juxtapapillary (jRH) and 12 peripherally (pRH). K-means cluster analysis distinguished seven exophytic (23.3%, 2 jRH, 5 pRH), nine endophytic (30%, 6 jRH, 3 pRH), and fourteen sessile (46.7%, 10 jRH, 4 pRH) growth patterns. Fractions of the flow signal in the IA, MA, and OA were 7.3 ± 3.3%, 89.3 ± 5.0%, and 3.4 ± 3.5% for exophytic RHs, 22.2 ± 7.4%, 65.6 ± 7.3%, and 12.1 ± 8.2% for sessile RHs, and 65.4 ± 5.7%, 26.6 ± 4.9%, and 8.0 ± 6.1% for endophytic RH.
Conclusion
OCTA contributes to further elucidating the morphology of RHs as a useful complementary diagnostic tool that can help to provide customized therapeutic approaches in the future and thus improve the effectiveness of RH treatment.
Autor:innen und Institutionen
- Eye Center, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.
- Department of Ophthalmology, University Hospital Brandenburg, Brandenburg Medical School, Brandenburg an der Havel, Germany.
- Jules Bordet Institute, Medical Oncology Department, University Hospital of Brussels, Brussels, Belgium.
- Medical Practice for Ophthalmology Priv.-Doz. Dr. med. Peter Maloca, Luzern, Switzerland.
- Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom.
- Ophtha-Lab, Department of Ophthalmology at St. Franziskus Hospital, Muenster, Germany.
ORCID-Profile: Stefan J Lang, Simone Nuessle, Michael Reich
Zitieren
APA
Laich, Y., Lang, S. J., Glatz, A., Farassat, N., Bucher, F., Nuessle, S., Böhringer, D., Lagrèze, W. A., Sideris, S., Maloca, P., Lange, C., Reinhard, T., Agostini, H., & Reich, M. (2025). Morphology of Retinal Hemangioblastoma in von Hippel-Lindau Disease Revealed by Optical Coherence Tomography Angiography. Klinische Monatsblätter für Augenheilkunde. https://doi.org/10.1055/a-2501-8628
Vancouver
Laich Y, Lang SJ, Glatz A, Farassat N, Bucher F, Nuessle S, et al. Morphology of Retinal Hemangioblastoma in von Hippel-Lindau Disease Revealed by Optical Coherence Tomography Angiography. Klinische Monatsblätter für Augenheilkunde. 2025. doi:10.1055/a-2501-8628
BibTeX
@article{Laich2025,
author = {Laich, Yannik and Lang, Stefan J and Glatz, Andreas and Farassat, Navid and Bucher, Felicitas and Nuessle, Simone and Böhringer, Daniel and Lagrèze, Wolf Alexander and Sideris, Spyridon and Maloca, Peter and Lange, Clemens and Reinhard, Thomas and Agostini, Hansjürgen and Reich, Michael},
title = {Morphology of Retinal Hemangioblastoma in von Hippel-Lindau Disease Revealed by Optical Coherence Tomography Angiography},
journal = {Klinische Monatsblätter für Augenheilkunde},
year = {2025},
doi = {10.1055/a-2501-8628}
}
EUVIMED